Jason was Senior Vice President of Business Development at Cambridge Antibody Technology (CAT) from 1996 to 2004. During that period he completed over 20 multi-faceted transactions with, for example, Eli Lilly, Wyeth, Abbott, AstraZeneca, ZymoGenetics, Human Genome Sciences, Genzyme, Amgen, Pfizer, Elan, Merck, Chugai, and Incyte. In addition to raising finance from the public markets, these deals generated approximately £90 million in corporate equity and £100 million in paid or committed fees. As a key member of CAT’s Executive Group, Jason helped the company grow from 30 to nearly 300 staff, raise £41 million in its IPO in March 1997 and £93 million in its follow-on offering in March 2000, list on the NASDAQ in the US and initiate, with CAT’s partners, seven multi-indication clinical trial programs. Until 1996 Jason was a Director of Corporate Finance at Ernst & Young LLP based in the UK and latterly in Palo Alto, California, where he advised and assisted biotech and pharmaceutical companies with corporate finance, business development and strategic consulting projects.Jason is a qualified Civil & Structural Engineer, a Member of the Institute of Chartered Accountants in England & Wales, a Member of the Institute of Directors, and a Fellow of the Royal Institution.

Jason acts as CEO of our portfolio company Funxional Therapeutics, and advises Total Medical Ventures on licensing, corporate transactions and business planning.